Acurx Pharmaceuticals
ACXP
18 hedge funds and large institutions have $345K invested in Acurx Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 5 closing their positions.
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
40% more capital invested
Capital invested by funds: $247K → $345K (+$98.3K)
13% more funds holding
Funds holding: 16 → 18 (+2)
2.65% more ownership
Funds ownership: 4% → 6.65% (+2.6%)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$199K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$112K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$81.1K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$59.5K |
| 5 |
Jane Street
New York
|
+$51.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$72.1K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$37.3K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$37K |
| 4 |
GWSG
GPS Wealth Strategies Group
Centennial,
Colorado
|
-$5.26K |
| 5 |
Citigroup
New York
|
-$2.17K |
ACXP Hedge Fund Activity: Q4 2025 in Review
18 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Acurx Pharmaceuticals (ACXP) for Q4 2025, worth a combined $345K — up 40% from $247K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ACXP positions and 5 closed out — a net gain of 2 holders — while 3 added to existing stakes and 5 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $199K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $72.1K sold.
- 18 institutional investors held Acurx Pharmaceuticals (ACXP) as of Q4 2025, up from 16 in Q3 2025.
- Funds reported $345K of Acurx Pharmaceuticals stock for Q4 2025, up 40% quarter-over-quarter.
- 7 funds opened new Acurx Pharmaceuticals positions in Q4 2025 and 5 closed out, a net change of +2 holders.
- The largest Acurx Pharmaceuticals buyer in Q4 2025 was Millennium Management, an estimated $199K added.
- The largest Acurx Pharmaceuticals seller in Q4 2025 was Susquehanna International Group, an estimated $72.1K sold.
Based on aggregated 13F filings for Q4 2025.